Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 10/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 4/20 | 0.38 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12979592 | 0.84 | MALT1 (0.48) | PTGER1MEN1RAB9AKMT2A | |
| SCHEMBL12979599 | 0.82 | NR1H2 (0.49) | MEN1NPC1RAB9AKMT2ASLC22A12 | |
| SCHEMBL31130145 | 0.74 | SLC16A3 (0.63) | MEN1NPC1RAB9AKMT2ASLC16A3 | |
| SCHEMBL31130236 | 0.73 | SLC16A3 (0.52) | PTGER1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL18307410 | 0.73 | SLC16A3 (0.60) | MEN1NPC1RAB9AKMT2ASLC16A3 | |
| SCHEMBL14622603 | 0.71 | KMT2A (0.48) | PTGER1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL20239469 | 0.71 | SLC16A3 (0.63) | MEN1NPC1RAB9AKMT2ASLC16A3 | |
| SCHEMBL20239628 | 0.70 | SLC16A3 (0.66) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL29819593 | 0.70 | SLC16A3 (0.66) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL3712001 | 0.70 | MALT1 (0.51) | PTGER1MEN1KMT2ASLC16A3SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | PTGER1 117/4885MEN1 3666/4885NPC1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.